hm15912
Peptideexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04076293)
Timeline
Indications
Mechanism of action
GLP2R agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05711381 | Phase 1 | Dec 2, 2022 | Hanmi Pharmaceutical |
| NCT04775706 | Phase 2 | Oct 31, 2021 | Hanmi Pharmaceutical |
| NCT04076293 | Phase 1 | Sep 30, 2019 | Hanmi Pharmaceutical |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 3 | 3 | 2 | 2019 |
1 organizations
Page 1 / 1